X B Wang1, R Pirskanen, R Giscombe, A K Lefvert. 1. Department of Respiratory Medicine, PuTuo Hospital, Shanghai University of TCM, Shanghai, China. xiongbiao6@yahoo.com
Abstract
OBJECTIVES: The molecular mechanisms underlying the regulation of the CD152 (CTLA-4) gene are largely unknown. Two single nucleotide polymorphisms (SNPs) located in the promoter region are suspected to contribute to the pathogenesis of myasthenia gravis (MG) through regulation of gene expression. SETTING, SUBJECTS AND DESIGN: One hundred and sixty-five unrelated Swedish-Caucasian patients with MG (103 females and 62 males, age 17 to 92 years) and 148 ethnically matched healthy individuals were studied. Gene typing of two SNPs (T/C(-1772) and A/G(-1661)) and quantification of soluble CD152 were performed in the patients. Besides the association studies, the function of these two SNPs is characterized. RESULTS: We present new genetic associations of two SNPs in the CD152 gene with human MG. These SNPs located in the promoter region are involved in transcriptional binding activity for Nuclear Factor I (NF-1) and c/EBPbeta, as demonstrated using chromatin immunoprecipitation and electromobility shift assay. MG patients with the T/C(-1772) polymorphism have elevated levels of sCD152 in sera. CONCLUSIONS: The two SNPs in the promoter region are associated with MG and might cause abnormal alternative splicing and affect the expression of CD152, thereby contributing to the pathogenesis of MG.
OBJECTIVES: The molecular mechanisms underlying the regulation of the CD152 (CTLA-4) gene are largely unknown. Two single nucleotide polymorphisms (SNPs) located in the promoter region are suspected to contribute to the pathogenesis of myasthenia gravis (MG) through regulation of gene expression. SETTING, SUBJECTS AND DESIGN: One hundred and sixty-five unrelated Swedish-Caucasian patients with MG (103 females and 62 males, age 17 to 92 years) and 148 ethnically matched healthy individuals were studied. Gene typing of two SNPs (T/C(-1772) and A/G(-1661)) and quantification of soluble CD152 were performed in the patients. Besides the association studies, the function of these two SNPs is characterized. RESULTS: We present new genetic associations of two SNPs in the CD152 gene with humanMG. These SNPs located in the promoter region are involved in transcriptional binding activity for Nuclear Factor I (NF-1) and c/EBPbeta, as demonstrated using chromatin immunoprecipitation and electromobility shift assay. MGpatients with the T/C(-1772) polymorphism have elevated levels of sCD152 in sera. CONCLUSIONS: The two SNPs in the promoter region are associated with MG and might cause abnormal alternative splicing and affect the expression of CD152, thereby contributing to the pathogenesis of MG.
Authors: Lei Cao-Lei; Salomon Carlos Leija; Robert Kumsta; Stefan Wüst; Jobst Meyer; Jonathan D Turner; Claude P Muller Journal: Hum Genet Date: 2011-01-15 Impact factor: 4.132
Authors: Douglas B Johnson; Vita Saranga-Perry; Patrick J M Lavin; W Bryan Burnette; Stephen W Clark; David R Uskavitch; Deborah E Wallace; Mark A Dickson; Ragini R Kudchadkar; Jeffrey A Sosman Journal: J Clin Oncol Date: 2014-04-28 Impact factor: 44.544
Authors: Alan E Renton; Hannah A Pliner; Carlo Provenzano; Amelia Evoli; Roberta Ricciardi; Michael A Nalls; Giuseppe Marangi; Yevgeniya Abramzon; Sampath Arepalli; Sean Chong; Dena G Hernandez; Janel O Johnson; Emanuela Bartoccioni; Flavia Scuderi; Michelangelo Maestri; J Raphael Gibbs; Edoardo Errichiello; Adriano Chiò; Gabriella Restagno; Mario Sabatelli; Mark Macek; Sonja W Scholz; Andrea Corse; Vinay Chaudhry; Michael Benatar; Richard J Barohn; April McVey; Mamatha Pasnoor; Mazen M Dimachkie; Julie Rowin; John Kissel; Miriam Freimer; Henry J Kaminski; Donald B Sanders; Bernadette Lipscomb; Janice M Massey; Manisha Chopra; James F Howard; Wilma J Koopman; Michael W Nicolle; Robert M Pascuzzi; Alan Pestronk; Charlie Wulf; Julaine Florence; Derrick Blackmore; Aimee Soloway; Zaeem Siddiqi; Srikanth Muppidi; Gil Wolfe; David Richman; Michelle M Mezei; Theresa Jiwa; Joel Oger; Daniel B Drachman; Bryan J Traynor Journal: JAMA Neurol Date: 2015-04 Impact factor: 18.302